PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise against rare childhood lymphoma
Disease control CompletedThis study tested a treatment called DA-EPOCH-Rituximab in 47 children and teens with a rare type of lymphoma (PMLBL). The goal was to see if this combination of chemotherapy and a targeted antibody could improve how long patients stay cancer-free. Participants received the drug …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 26, 2026 08:18 UTC
-
CAR-T therapy shows promise in Long-Term Follow-Up for blood cancers
Disease control CompletedThis study followed 16 patients with various B-cell cancers (like lymphoma and leukemia) who had already received CLBR001 CAR-T cells. The goal was to check for long-term side effects and see how well the treatment controlled the disease over time. Researchers monitored new or la…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 26, 2026 08:13 UTC
-
Experimental CAR-T therapy shows promise for tough lymphomas
Disease control CompletedThis early-phase study tested a new treatment called BZ019 in 12 adults with certain types of B-cell lymphoma that had stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 20, 2026 11:55 UTC